VivoGenie Biosimilar Antibodies
VivoGenie Biosimilars
Functional-Grade biosimilars for animal pre-clinical In Vivo studies
Why choose VivoGenie Biosimilar Antibodies?
- Low-endotoxin levels | ≤ 1 EU/mg levels, & high purity (≥95%)
- Research | Designed for in vivo experiments, to study therapeutic effects, pharmacokinetics & other biological interactions
- Top targets | PD-L1, CTLA-4, HER-2 and + 80 more including Fc mutated biosimilars for pre-clinical studies.
Popular VivoGenie Biosimilars
Testimonials & Partners
"I ordered from AssayGenie for the first time and would like to share my satisfied impression. The article (Bevacizumab; IVMB0232) was used as a positive control and works excellently in Biacore SPR measurements and VEGF bioassay"
- G. Carsten, Fraunhofer (2024)
Citations
Product | Author | Citation |
|---|---|---|
Bikoriman et al. | ||
Leane et al. | ||
Rohani et al. | ||
Calvo et al. | ||
Turley et al. | ||
Wang et al. |
cGMP & ISO Certification
Quality is at the core of everything we do.
Manufactured in state-of-the-art facilities, our products meet the highest standards, including current Good Manufacturing Practicies) cGMP, ISO 9001:2015, and ISO 13485:2016 certifications. These ensure consistent quality, customer-focused innovation, and reliable performance in every batch.
VivoGenie Biosimilar Data
QC Data
Figure 1. Quality control for different lots of PD-1 [RMP1-14] antibody. All the in vivo antibodies undergo extensive quality control ensuring extreme lot-to-lot reproducibility. Endotoxin data for eight lots demonstrate that all lots were below the specification of ≤ 1 EU/mg as determined by the limulus amebocyte lysate (LAL) method (Fig. 1A). Analysis by size exclusion chromatography visualized by superimposing chromatograms for all nine lots, with overlapping retention times and minimal baseline noise (Fig. 1B). All lots show high purity as shown by non-reducing and reducing SDS-PAGE (Fig. 1C and 1D).
SDS- Page Data
Specification Data
With low endotoxin levels (≤1.0 EU/mg) and minimal aggregation (≥95% monomer verified by SEC), they are ideal for sensitive applications. Formulated in sterile PBS (pH 7.2) without preservatives, stabilizers, or carrier proteins.
Meet Some of the Genie Team!
Shane, Sales
Natalia, Tech Support
Chris, Sales
Beatriz, Logistics
Marina, Tech Support
Miren, Sales
José, Sales
David, Sales
Joe, Sales
Shivaun, Logistics
Vinothini, Data Analyst
Bala, Data Analyst
Frequently Asked Questions
- Preclinical drug screening
- Assay development and validation (e.g., ELISA, Western Blot, Flow Cytometry)
- Mechanism of action studies
- Comparative studies against reference biologics
Biosimilar Resources - Blogs & Podcast Episodes
Quick Facts About EnavatuzumabWhat is Enavatuzumab?Enavatuzumab is a monoclonal antibody targeting the TWEAK receptor (Fn14), pivotal in tumor growth and immune regulation.What is the mechanism of action for Enavatuzumab?Enavatuzumab binds to Fn14, inhibiting signaling pathways that promote tumor cell proliferation and survival while [...]Quick Facts About EnavatuzumabWhat is Enavatuzumab?Enavatuzumab is a monoclonal antibody targeting the TWEAK receptor (Fn14), pivotal in tumor growth and immune regulation.What is the mechanism of action for Enavatuzumab?Enavatuzumab binds to Fn14, inhibiting signaling pathways that promote tumor cell proliferation and survival while [...]
Quick Facts About SiltuximabWhat is Siltuximab?Siltuximab is a monoclonal antibody targeting interleukin-6 (IL-6), a cytokine involved in inflammation and immune regulation.What is the mechanism of action for Siltuximab?Siltuximab binds to IL-6, preventing it from interacting with its receptor and mitigating downstream pro-inflammatory signaling.What [...]
Related Products
Additional Resources
